Dynamic changes in serum gelsolin combined with clinical parameters to construct a predictive model for mucosal healing in inflammatory bowel disease: A prospective cohort study
Abstract
Mucosal healing represents a critical therapeutic endpoint in inflammatory bowel disease (IBD), yet reliable noninvasive predictive biomarkers remain limited. Serum gelsolin (GSN) has emerged as a potential inflammatory biomarker, but its dynamic changes and predictive value for mucosal healing have not been systematically investigated. This study aimed to develop and internally validate a predictive model integrating dynamic GSN changes with clinical parameters for forecasting 6-month mucosal healing in IBD patients. We enrolled 298 IBD patients (182 Crohn disease, 116 ulcerative colitis) from a tertiary referral center and collected baseline and 6-month follow-up data including serum GSN levels, endoscopic scores, and clinical parameters. The primary endpoint was mucosal healing at 6 months (Mayo endoscopic score ≤1 or SES-CD
Fields of Study & Subjects
Inflammatory Bowel Disease
Gut microbiota and health
Therapeutic Uses of Natural Elements
Publication details
- Journal / source
- Medicine
- Publisher
- Ovid Technologies (Wolters Kluwer Health)
- Volume
- 105
- Issue
- 20
- Pages
- e48832–e48832
- Publication date
- 15 May 2026
- Language
- EN